https://www.live-feeds.com/feed/fda-approves-alzheimer-s-blood-test-developed-by-roche-and-eli-lillyContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-approves-alzheimer-s-blood-test-developed-by-roche-and-eli-lillyhttps://www.live-feeds.com/feed/fda-approves-alzheimer-s-blood-test-developed-by-roche-and-eli-lilly#u50016Thu, 27 Aug 2026 12:00:25 +0000The FDA approved a biomarker blood test developed by Roche and Eli Lilly to detect Alzheimer's disease, according to a Roche announcement on August 24. The test is authorized for use in primary and specialty care settings. Labcorp and Quest Diagnostics plan to offer the test, which previously received CE mark certification. While some reports suggest the test is for patients 55 and older, other data indicates it is authorized for Americans as young as 40. The test offers a less invasive alternative to previous diagnostic standards for identifying disease biomarkers.Why it mattersEarly det https://www.live-feeds.com/feed/fda-approves-alzheimer-s-blood-test-developed-by-roche-and-eli-lillyhttps://www.live-feeds.com/feed/fda-approves-alzheimer-s-blood-test-developed-by-roche-and-eli-lilly#u48010Tue, 25 Aug 2026 07:01:49 +0000The FDA has cleared a blood test developed by Roche and Eli Lilly to assist in the evaluation of Alzheimer's disease. This biomarker test is available for use in both primary and specialty care settings. It is the first of its kind to receive approval and is authorized for use in Americans as young as 40 years old. The test provides a less invasive method for detecting biomarkers associated with the disease compared to previous diagnostic standards.Why it mattersTraditionally, confirming Alzheimer's required more invasive procedures or expensive imaging. A blood-based biomarker test